---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-26-000036"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2026-07-30T20:14:23+00:00"
generated_at: "2026-07-30T20:15:23.436073+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q2 revenue $390M (+14.9% YoY); net income $34.8M; pending BSX acquisition

## Summary
- Revenue $390.0M, up 14.9% YoY; global thrombectomy $259.0M (+12.5%), embolization & access $131.1M (+20.0%).
- Gross profit margin 67.9%, up 1.9 percentage points YoY.
- Income from operations $41.0M; net income $34.8M.
- Operating expenses include $6.9M acquisition-related costs for pending Boston Scientific acquisition.
- Company will not provide FY2026 guidance due to pending acquisition.

## SEC filing metadata
- accession: 0001321732-26-000036
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2026-07-30T20:14:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173226000036/0001321732-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173226000036/pen-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-26-000036
- JSON: https://secwatch.observer/filing/0001321732-26-000036.json
- Plain text: https://secwatch.observer/filing/0001321732-26-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.